T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zoom
ZM
|
+$3.3B |
| 2 |
Eli Lilly
LLY
|
+$2.75B |
| 3 |
AstraZeneca
AZN
|
+$1.98B |
| 4 |
Coupang
CPNG
|
+$1.54B |
| 5 |
Fortinet
FTNT
|
+$1.48B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NXP Semiconductors
NXPI
|
+$2.34B |
| 2 |
Morgan Stanley
MS
|
+$2.26B |
| 3 |
Airbnb
ABNB
|
+$2.04B |
| 4 |
Qualcomm
QCOM
|
+$1.95B |
| 5 |
NVIDIA
NVDA
|
+$1.81B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 23.35% |
| 2 | Healthcare | 16.19% |
| 3 | Consumer Discretionary | 15.55% |
| 4 | Financials | 12.84% |
| 5 | Communication Services | 12.27% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2351
HealthStream
HSTM
$849M
| $505K | ﹤0.01% |
22,614
-26
| -0.1% | -$620 |
|
2352
National Presto Industries
NPK
$987M
| $505K | ﹤0.01% |
4,949
-196
| -4% | -$19.3K |
|
2353
Workhorse Group
WKHS
$33.1M
| $505K | ﹤0.01% |
12
-8
| -40% | -$575K |
|
2354
West Bancorporation
WTBA
$511M
| $505K | ﹤0.01% |
20,979
-5
| -0% | -$114 |
|
2355
Liberty Latin America Class A
LILA
$1.67B
| $501K | ﹤0.01% |
57,502
+26,198
| +84% | +$216K |
|
|
AERI
2356
DELISTED
Aerie Pharmaceuticals
AERI
| $501K | ﹤0.01% |
28,053
+52
| +0.2% | +$898 |
|
|
HSII
2357
DELISTED
Heidrick & Struggles
HSII
| $499K | ﹤0.01% |
13,972
+6
| +0% | +$204 |
|
|
VXRT
2358
DELISTED
Vaxart
VXRT
| $499K | ﹤0.01% |
82,544
-1,135,953
| -93% | -$8.74M |
|
|
TRTX
2359
TPG RE Finance Trust
TRTX
$616M
| $498K | ﹤0.01% |
44,462
-60
| -0.1% | -$657 |
|
|
ORBC
2360
DELISTED
ORBCOMM, Inc.
ORBC
| $498K | ﹤0.01% |
65,281
-43,895
| -40% | -$346K |
|
2361
Veeco
VECO
$3.28B
| $497K | ﹤0.01% |
23,942
-1,967
| -8% | -$40.9K |
|
2362
Artivion
AORT
$1.39B
| $496K | ﹤0.01% |
21,970
-3,432
| -14% | -$84K |
|
|
GOOD
2363
Gladstone Commercial Corp
GOOD
$641M
| $496K | ﹤0.01% |
25,344
-98
| -0.4% | -$1.85K |
|
2364
BioXcel Therapeutics
BTAI
$34.9M
| $495K | ﹤0.01% |
716
+5
| +0.7% | +$4.02K |
|
2365
CareCloud
CCLD
$104M
| $495K | ﹤0.01% |
59,600
+17,400
| +41% | +$172K |
|
2366
The Greenbrier Companies
GBX
$1.42B
| $495K | ﹤0.01% |
10,475
-5,302
| -34% | -$227K |
|
2367
Interparfums
IPAR
$3.7B
| $495K | ﹤0.01% |
6,979
-902
| -11% | -$61.2K |
|
|
AHRT
2368
AH Realty Trust
AHRT
$506M
| $491K | ﹤0.01% |
39,117
+5,180
| +15% | +$63.3K |
|
2369
Comtech Telecommunications
CMTL
$52.7M
| $489K | ﹤0.01% |
19,669
-6,845
| -26% | -$174K |
|
2370
Forrester Research
FORR
$224M
| $489K | ﹤0.01% |
11,522
-24
| -0.2% | -$1.04K |
|
2371
CEL-SCI Corp
CVM
$26M
| $488K | ﹤0.01% |
1,070
+78
| +8% | +$42.6K |
|
2372
Ethan Allen Interiors
ETD
$583M
| $488K | ﹤0.01% |
17,664
+55
| +0.3% | +$1.38K |
|
2373
Willdan Group
WLDN
$1.29B
| $488K | ﹤0.01% |
11,878
-716
| -6% | -$32.9K |
|
2374
Sutro Biopharma
STRO
$353M
| $487K | ﹤0.01% |
2,140
+43
| +2% | +$10.2K |
|
2375
Vera Bradley
VRA
$94.7M
| $486K | ﹤0.01% |
48,090
+36,196
| +304% | +$341K |
|
Similar funds
T. Rowe Price Associates's Q1 2021 Portfolio in Review
As of Q1 2021, T. Rowe Price Associates held 2,908 positions worth $999B, up 2.5% from $974B the previous quarter. Its ten largest holdings account for 24% of the portfolio.
T. Rowe Price Associates's Q1 2021 filing shows 248 new, 1,171 increased, 1,334 reduced and 66 closed positions. Its largest new stake was Coupang: 33,380,859 shares worth $1.63B. The largest sale was NXP Semiconductors, an estimated $2.34B.
By sector, the portfolio is most concentrated in Technology at 23% of assets, down from 25% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q1 2021 buy was Coupang: 33,380,859 shares worth $1.63B.
- T. Rowe Price Associates added most to Zoom in Q1 2021, an estimated $3.3B increase.
- T. Rowe Price Associates's biggest Q1 2021 reduction was NXP Semiconductors, cutting an estimated $2.34B.
- T. Rowe Price Associates fully exited CONCHO RESOURCES INC. in Q1 2021, selling an estimated $205M.
- T. Rowe Price Associates's ten largest holdings make up 24% of its $999B portfolio in Q1 2021.
- T. Rowe Price Associates opened 248 new positions and closed 66 in Q1 2021.
- T. Rowe Price Associates's portfolio value rose 2.5% quarter-over-quarter to $999B.
Based on T. Rowe Price Associates's 13F filing for Q1 2021, filed 17 May 2021.